Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.91 USD | -0.15% | -0.31% | +95.49% |
05-02 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-30 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+95.49% | 2.27B | |
+18.40% | 47.02B | |
+48.77% | 41.86B | |
+0.61% | 41.76B | |
-4.27% | 28.8B | |
+11.75% | 26.05B | |
-21.82% | 19.15B | |
+3.64% | 12.55B | |
+28.22% | 12.34B | |
-4.46% | 11.82B |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- JPMorgan Adjusts Price Target on Dyne Therapeutics to $18 From $24, Maintains Overweight Rating